Pfizer - zu Unrecht im Keller

Ausbruch dann wenn 39 $ durchbrochen,  die 37 $ müssen halten.....hält sich aber stabil aktuell um die 38$ gutes Zeichen.....

HEALTH AND SCIENCE
Trump says U.S. may have coronavirus vaccine ‘far in advance’ of end of the year
PUBLISHED MON, AUG 3 20206:22 PM

He mentioned vaccine candidates from drug companies Pfizer and Moderna, which both began late-stage trials for their leading vaccine candidates last week, and have already vaccinated “several hundred people,” according to senior administration officials.  

bezüglich Covid 19
Das große Rennen um den Corona-Impfstoff
Die Pandemie hat die Welt im Griff. Es braucht dringend einen Impfstoff – seit Wochen wetteifern Unternehmen und Staaten darum, wer ihn als Erster findet. Es geht allerdings nicht nur um die Entwicklung

von Monika Dunkel
3. August 2020

link:
www.capital.de/wirtschaft-politik/...-um-den-corona-impfstoff

In 2018, the U.S. Food and Drug Administration (FDA) approved LORBRENA for the treatment of patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease. This indication is approved under accelerated approval based on tumor response rate and duration of response. CROWN is the confirmatory study for the conversion to full approval. Based on the positive outcome of the CROWN trial, we intend to share the results with the FDA and other health authorities to support conversion to full approval and to seek approval for an indication that includes previously untreated ALK-positive metastatic NSCLC.

CROWN is a Phase 3, randomized, open-label, parallel 2-arm study in which 296 people with previously untreated advanced ALK-positive NSCLC were randomized 1:1 to receive LORBRENA monotherapy or XALKORI monotherapy. The primary endpoint of the CROWN trial is PFS based on blinded independent central review (BICR). Secondary endpoints include overall survival, PFS based on investigator’s assessment, objective response (OR) based on BICR and on investigator’s assessment; intracranial OR (IC-OR), IC time to progression, duration of response (DR), IC-DR, time to tumor response (TTR), IC-TTR (all by BICR); PFS2 based on investigator’s assessment, and safety.

www.globenewswire.com
Pfizer and BioNTech to Supply Canada with their BNT162 mRNA-Based Vaccine Candidate
August 05, 2020 08:00 ET
Supply to be provided over the course of 2021, subject to Health Canada approval

Agreement is part of Pfizer’s and BioNTech’s global commitment to help address the pandemic

Pfizer and BioNTech began a Phase 2b/3 safety and efficacy trial and remain on track to seek regulatory review as early as October 2020, and to manufacture globally up to 100 million doses by the end of 2020 and approximately 1.3 billion doses by the end of 2021
KIRKLAND, Quebec and MAINZ, Germany, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pfizer Canada and BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced an agreement with the Government of Canada to supply their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and Health Canada approval.

Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses. As requested by the Government of Canada, deliveries of the vaccine candidate are planned for over the course of 2021.

“We continue to be committed to partnering with the Canadian government to help fight this pandemic and are pleased with their collaborative approach to addressing a national COVID-19 immunization strategy with public health officials,” said Cole C. Pinnow, President, Pfizer Canada . “With our combined efforts, we know there is no health challenge that we cannot address.”

“As the development of effective COVID-19 vaccines continues around the world, we commend the work of Pfizer and BioNTech, which will provide Canadians access to a vaccine candidate for the virus. This agreement is another critical step in our government’s efforts to keep Canadians safe and healthy as the pandemic continues to evolve,” said The Honourable Anita Anand, Minister of Public Services and Procurement, Government of Canada .

“In the face of this global health crisis, Pfizer’s purpose – breakthroughs that change patients’ lives – has taken on an even greater urgency,” said Albert Bourla, Chairman and CEO, Pfizer . “We’re harnessing our scientific expertise, and we’re marshaling our manufacturing resources in an effort to ensure that the vaccine would be available as soon as possible, if our clinical trials prove successful and regulatory approval is granted.”

“This agreement is part of our commitment to address the pandemic by supporting global supply of our vaccine candidate. Our teams are working diligently to advance the lead product candidate through clinical development in order to seek regulatory review as early as October. At the same time, Pfizer and BioNTech continue to scale up manufacturing capacities to be able to produce up to 100 million doses in 2020 and more than one billion doses in 2021. Since we initiated Project Lightspeed our aim has always been clear: Making a potential vaccine available to the public as quickly as possible – worldwide. This agreement is yet another step in that direction,” said Sean Marett, Chief Business and Chief Commercial Officer at BioNTech .

The BNT162 program is based on BioNTech’s proprietary mRNA technology and supported by Pfizer’s global vaccine development and manufacturing capabilities. The vaccine development program is evaluating at least four experimental vaccine candidates, each of which represents a unique combination of messenger RNA (mRNA) format and target antigen. The BNT162 vaccine candidates are undergoing clinical studies and are not currently approved for distribution anywhere in the world. Both collaborators are committed to developing these novel vaccines with pre-clinical and clinical data at the forefront of all their decision-making.

Recently, two of the companies’ four investigational vaccine candidates – BNT162b1 and BNT162b2 – received Fast Track designation from the U.S. Food and Drug Administration (FDA). This designation was granted based on preliminary data from Phase 1/2 studies that are currently ongoing in the United States and Germany as well as animal immunogenicity studies.

On July 27, Pfizer and BioNTech announced that following extensive review of preclinical and clinical data from Phase 1/2 clinical trials, and in consultation with the U.S. FDA’s Center for Biologics Evaluation and Research (CBER) and other global regulators, the companies selected the BNT162b2 vaccine candidate to move forward into a Phase 2/3 study. BNT162b2 encodes an optimized SARS-CoV-2 full length spike glycoprotein (S), which is the target of virus neutralizing antibodies. In the late-stage trial, the companies will study a 30 µg dose level in a 2-dose-regimen among up to 30,000 participants aged 18 to 85 years. It is expected to include approximately 120 sites globally including in regions with significant expected SARS-CoV-2 transmission. BNT162b2 has received Fast Track designation from the U.S. FDA.

Assuming clinical success, Pfizer and BioNTech are on track to seek regulatory review for BNT162b2 as early as October 2020 and, if regulatory authorization or approval is obtained, plan to supply up to 100 million doses worldwide by the end of 2020 and approximately 1.3 billion doses by the end of 2021.

In addition to engagements with governments, Pfizer and BioNTech have provided an expression of interest for possible supply to the COVAX Facility, a mechanism established by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and World Health Organization (WHO) that aims to provide governments, including those in the emerging markets, with early access to a large portfolio of COVID-19 candidate vaccines using a range of technology platforms, produced by multiple manufacturers across the world.  

Nachbörse 39,05  $       +0,60 (1,56 %)

An Eliquis patent ruling expected in the first week of August.  vermutlich das
Eliquis-Patententscheidung positiv entschieden

Bristol-Myers Squibb Co. und Pfizer Inc. haben ein Gerichtsurteil gewonnen, in dem Patente auf ihren Blockbuster-Blutverdünner Eliquis bestätigt wurden.

Die Unternehmen, die Gewinne aus dem Verkauf des Arzneimittels teilen, haben bewiesen, dass Hersteller von Generika, darunter Sigmapharm Laboratories LLC, gültige Patente verletzen würden, sagte ein Bundesrichter in Wilmington, Delaware.

Was in aller Hölle tummelt sich die Pfizer im ING Forum..
Meldet doch mal den Mist... vielleicht  reagiert der Moderator wenn er von VIELEN auf den Fehler hingewiesen  wird

sind wir hier im ING-Forum  oder auf der ING Seite ?  NEIN  ...   somit uninteressanter Beitrag

der Gewinn im Laufe des Tages abverkauft.
Mittlerweile sind sehr viele gute News zusammenkommen. Wird Zeit dass es zu einem Ausbruch kommt.
Ende September sollen auch die  ersten Daten über den Verlauf des impfstoffes von Phase 3 kommen.

not good !  die relative Stärke lässt auch nach.....  

war für Biontech gemeint ;-)

Wir sind Hier ...
Im Onvista Forum


Diskussionen zu ING Group


Für Alle die Lesen können....

Ist das die Überschrift.

- Sie können pro Posting einen AG-Filter oder einen Listen-Filter setzen

Du bist schon witzig hast dich hier verlaufen und hast es nicht mal geschnallt.

Also doch nicht beim klaren Verstand.

..."When Albert Bourla took over as CEO of Pfizer in January 2019, he said he wanted the pharmaceutical giant to be a more focused, innovative, science-based company. Bourla now finds himself at the forefront of developing and testing a COVID-19 vaccine in partnership with Germany's BioNTech. Underway with a late-stage clinical trial for its vaccine, if successful, Pfizer said they could supply up to 100 million doses of the vaccine by the end of 2020. Bourla will discuss the timeline for a safe and effective vaccine and the state of the health industry during these uncertain times"..........

Pfizer gibt Vereinbarung mit Gilead zur Herstellung von Remdesivir zur Behandlung von COVID-19 bekannt
07. August 2020 08:00 Uhr Eastern Daylight Time
NEW YORK - (BUSINESS WIRE) - Pfizer Inc. (NYSE: PFE) gab heute eine mehrjährige Vereinbarung mit Gilead Sciences, Inc. über die Herstellung und Lieferung von Gileads antiviralem Remdesivir als eine von mehreren externen Fertigungsorganisationen bekannt, die dies unterstützen Erweiterung des Angebots an Prüfpräparaten für COVID-19. Im Rahmen der Vereinbarung wird Pfizer Auftragsfertigungsdienstleistungen in Pfizers Werk in McPherson, Kansas, zur Herstellung und Lieferung von Remdesivir für Gilead erbringen.

All of that is water under the bridge. The more important question is: Should you invest $1,000 in Pfizer now that we're in another recession?

www.laborpraxis.vogel.de/...n-sars-cov-2-fuer-japan-a-953389/

Is Pfizer Stock a Buy?
It's been a tough year for the healthcare giant, but could a turnaround be in the cards?

bis die Entscheidung mit dem Impfstoff fällt.

link:
www.notonlyequity.com/...lued-health-care-stocks-august-2020/

Metrics:
Healthcare sector
Large Cap
Competitive advantage
Trading lower than their Price/Fair Value ( Morningstar DCF model)
P/E < P/E 5Yrs
P/E < than benchmark ( MSCI Health Care Index)
P/E > Fwd P/E
Positive FCF
Postive EPS forecast

Insider BLAYLOCK RONALD E:
Acquired 13,000 of Common Stock at average price $38.55 on 2020-08-06

Sogar in DE schnell

www.n-tv.de/panorama/...g-im-Oktober-an--article21626512.html